TherapeuticsMD, Inc. (NASDAQ:TXMD) Director Cooper C. Collins bought 1,000,000 shares of the company’s stock in a transaction that occurred on Thursday, November 18th. The shares were acquired at an average price of $0.58 per share, for a total transaction of $580,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
NASDAQ:TXMD opened at $0.60 on Thursday. TherapeuticsMD, Inc. has a 12 month low of $0.55 and a 12 month high of $2.75. The stock has a 50 day moving average of $0.71 and a two-hundred day moving average of $0.92. The firm has a market cap of $255.99 million, a P/E ratio of -1.26 and a beta of 1.79.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Thursday, November 11th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01). During the same period in the prior year, the firm posted ($0.10) earnings per share. Analysts anticipate that TherapeuticsMD, Inc. will post -0.41 earnings per share for the current year.
Large investors have recently bought and sold shares of the business. Schonfeld Strategic Advisors LLC purchased a new stake in TherapeuticsMD during the 2nd quarter worth approximately $28,000. Procyon Private Wealth Partners LLC purchased a new stake in shares of TherapeuticsMD in the second quarter valued at approximately $38,000. Royal Bank of Canada grew its position in shares of TherapeuticsMD by 767.7% in the first quarter. Royal Bank of Canada now owns 32,973 shares of the company’s stock valued at $43,000 after purchasing an additional 29,173 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of TherapeuticsMD in the third quarter valued at approximately $27,000. Finally, Qube Research & Technologies Ltd grew its position in shares of TherapeuticsMD by 70.3% in the second quarter. Qube Research & Technologies Ltd now owns 37,480 shares of the company’s stock valued at $45,000 after purchasing an additional 15,475 shares in the last quarter. Institutional investors own 44.67% of the company’s stock.
TherapeuticsMD, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm’s technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Further Reading: Overweight
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.